Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 6/20 | 0.36 |
| ▸ | RAB9A | P51151 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485534 | 0.84 | PTGS1 (0.57) | HRH4HRH3PTGS1PTGS2MAPT | |
| SCHEMBL17512464 | 0.84 | TGFBR1 (0.44) | HRH4HRH3PTGS1PTGS2MAPT | |
| SCHEMBL16376280 | 0.82 | RAB9A (0.50) | HRH4HRH3PTGS1PTGS2MAPT | |
| SCHEMBL16396042 | 0.82 | RAB9A (0.48) | HRH4HRH3MAPTCYP1A2CYP3A4 | |
| SCHEMBL15223780 | 0.81 | HRH4 (0.41) | HRH4HRH3PTGS1PTGS2MAPT | |
| SCHEMBL12286501 | 0.80 | POLB (0.53) | PTGS1MAPTPOLBEGLN1NPC1 | |
| SCHEMBL3545619 | 0.80 | KDM4E (0.64) | MAPTCYP1A2CYP3A4KDM4EPOLB | |
| SCHEMBL8176307 | 0.79 | APP (0.48) | HRH4HRH3PTGS1PTGS2KDM4E | |
| SCHEMBL20646875 | 0.79 | HRH4 (0.61) | HRH4HRH3MAPTKDM4EPOLB | |
| SCHEMBL1500263 | 0.79 | PIK3CG (0.51) | HRH4HRH3PTGS1PTGS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | MACROGENICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MACROGENICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-9890159-B2 | Process for making duocarmycin prodrugs | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2018-02-13 | — | — | US | disclosed |
| US-20170145006-A1 | PROCESS FOR MAKING DUOCARMYCIN PRODRUGS | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | CD47, ENPP2, CD2 | HRH4 1836/4885HRH3 1673/4885PTGS1 4253/4885 |
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | CD274, CD2, CD22 | HRH4 14/4885HRH3 4/4885PTGS1 4515/4885 |
| US-20170145006-A1 | PROCESS FOR MAKING DUOCARMYCIN PRODRUGS | UMPS, UNG, DNASE1 | HRH4 2140/4885HRH3 1756/4885PTGS1 4804/4885 |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | CD274, PDCD1, H1-3 | HRH4 46/4885HRH3 11/4885PTGS1 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.